Skip to main content
. 2015 Sep 23;35(38):13043–13052. doi: 10.1523/JNEUROSCI.2317-15.2015

Table 1.

Details of PD patients

ID Age Sex Year of diagnosis Medications UPDRS III DBS OFF UPDRS III DBS ON
STN1 58 M 2004 Sinemet, amantadine 64 36
STN2 73 M 2001 Madopar, rotigotine, entacapone, rasagiline 26 10
STN3 63 M 1994 Ropinirole, amitriptyline 55 37
STN4 64 M 1996 Sinemet, ropinirole, tolcapone, rasagiline 51 16
STN5 59 M 1996 Madopar, Stalevo 39 27
STN6 47 M 2009 Madopar, rotigotine, rasagiline 45 27
GPi1 58 M 2003 Sinemet, pramipexole 41 33
GPi2 72 F 2002 Sinemet, pramipexole 25 16
GPi3 77 M 2001 Stalevo, selegiline 35 30
GPi4 64 M 2003 Madopar 31 22
GPi5 58 M 1998 Sinemet, Stalevo, rotigotine, amantadine 19 11
GPi6 67 M 2006 Sinemet, Stalevo 35 19
GPi7 62 M 2007 Sinemet 40 21
GPi8 54 M 2005 Madopar, amantadine, entacapone, rasagiline 30 25

Unified Parkinson's Disease Rating Scale (UPDRS) part III scores are with DBS on and off (patients were on their medication in both cases). Sinemet contains levodopa and carbidopa; Stalevo contains levodopa, carbidopa, and entacapone; and Madopar contains levodopa and benserazide. M, Male; F, female.